Key facts
- GeneMind’s last known valuation is $269.3M (Mar 2025).
- It has raised $184.3M; the latest was Later Stage VC ($38.7M) in May 2025.
- Notable investors include Cowin Capital, IDG Capital, Fortune Capital, Legend Capital, Changde Caixin Financial Holding — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for GeneMind
- ·The full record, as it builds
Funding rounds
No funding rounds for GeneMind are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GeneMind
Developer of molecule sequencer and genome sequencing technology designed to provide solutions for noninvasive detection, disease diagnosis, and treatment. The company's technology includes single molecule direct sequencing, virtual terminator, and single molecule fluorescence sequencing algorithm, enabling clinics and medical institutions to provide genomic solutions effectively and affordably.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2012
- Website
- genemind.com/
- Ownership
- Privately Held (backing)
GeneMind doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeneMind shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeneMind in its N-PORT filings yet. We sweep new filings monthly.